Comparing the current results to its competitors, Quest Diagnostics Inc reported Revenue increase in the 2 quarter 2026 by 10.21 % year on year. The revenue growth was below Quest Diagnostics Inc's competitors' average revenue growth of 10.89 %, achieved in the same quarter.
Quest Diagnostics Inc's Comment on Competition and Industry Peers
The clinical testing industry remains fragmented, is highly competitive and is
subject to new competition. Competition is growing from non-traditional competitors.
Increased hospital acquisitions of physician practices enhance physician ties
to hospital-affiliated laboratories and may strengthen their competitive position.
New industry entrants with extensive resources may make acquisitions or expand
into our traditional areas of operations.
Overall company revenue, increased less, than total company revenues, at 10.21 % and lost market share, to approximately 14.42 %. << More on DGX Market Share.
*Market share is calculated based on total revenue.
January 9, 2024
Quest Diagnostics and Ultima Collaborate to Revolutionize Oncology and Clinical Diagnostics with Next-Generation Sequencing TechnologyIn a groundbreaking partnership, Quest Diagnostics, the leading provider of diagnostic information services, and Ultima Genomics, the developer of an innovative ultra-high throughput sequencing architecture, have joined forces to accelerate the deployment of Ultima s next-generation sequencing (NGS) technology in the field of oncology and other clinical areas. This collaboration aims to enhance patient access, affordability, and ultimately improve outcomes by expanding the utilization of highly accurate sequencing techniques.NGS technology has significantly advanced the field ...
Myriad Genetics Inc's business model revolves around providing molecular diagnostic testing services and developing innovative precision medicine solutions that help identify and personalize treatment options for patients across various medical specialties.
Labcorp Holdings Inc operates as a major healthcare diagnostics company, providing clinical laboratory tests and services to healthcare providers, pharmaceutical companies, and government agencies. Their business model emphasizes delivering accurate and timely test results to aid in patient diagnosis, treatment, and monitoring.
iSpecimen Inc's business model revolves around connecting researchers with the biospecimens they need for their scientific and medical studies. They serve as an intermediary platform that links healthcare organizations and biobanks to the research community, providing a streamlined process for sourcing human biosamples and associated data.
Sources:
Quest Diagnostics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Quest Diagnostics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
